Skip to content

Effect of RP-1701 on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Effect of RP-1701 on the Mild Cognitive Impairment for the Efficacy and Safety; A 12week, Multi-center, Randomized, Double-blind, Placebo-Controlled Clinical Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0004042
Enrollment
100
Registered
2019-06-10
Start date
2019-03-18
Completion date
Unknown
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Dietary Supplement : Treatment(combined Omijia etc extracts 1.5g/ day) gourp: Take 2 tablet 2 times per day after meal for 12 weeks Control (Placebo): Same way with treatment

Sponsors

Kyung Hee University Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Adult men and women aged from 55 t0 85 years old who complain memory loss 2) Those who can decipher Korean 3) CERAD-K memory score decreased from 1.0SD to less than 2.0SD compare to the same age and education level gruop (CERAD word list memory or word delayed recall or word recognition) 4) A person who agrees to participate in the test and has signed an informed consent form

Exclusion criteria

Exclusion criteria: 1) A person who is admitted to hospital with malignant tumor, severe cerebrovascular disease (cerebral infarction, cerebral hemorrhage, etc.), severe heart disease (unstable angina, myocardial infarction, arrhythmia requiring heart failure treatment) or 3 months after discharge 2) A person with disease causing cognitive impairment such as dementia, Parkinson's disease,cerebral infarction etc. 3) A person who has experience of administering drugs (antipsychotic drugs, degenerative disease agents, brain function improvers, tricyclic antidepressants) for dementia or other cognitive dysfunction within 4 weeks 4) A person whose daily dose of vitamin E preparation is 400 IU or more, or whose dosage decreasing is inevitable. 5) A person who have received estrogen replacement therapy (excluding topical application agents) within 2 months of the start of the test

Design outcomes

Primary

MeasureTime frame
ADAS-K(Alzheimer’s Disease Assessment Scale-Korean version)

Secondary

MeasureTime frame
ADCS-ADL(Alzheimer’s Disease Cooperative Study-Activities of Daily Living);Visual C.P.T

Countries

Korea, Republic of

Contacts

Public ContactJongWoo Paik

Kyung Hee University Hospital

paikjw@gmail.com+82-2-958-8419

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026